240 related articles for article (PubMed ID: 22728437)
1. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.
Littlepage LE; Adler AS; Kouros-Mehr H; Huang G; Chou J; Krig SR; Griffith OL; Korkola JE; Qu K; Lawson DA; Xue Q; Sternlicht MD; Dijkgraaf GJ; Yaswen P; Rugo HS; Sweeney CA; Collins CC; Gray JW; Chang HY; Werb Z
Cancer Discov; 2012 Jul; 2(7):638-51. PubMed ID: 22728437
[TBL] [Abstract][Full Text] [Related]
2. The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value.
Cohen PA; Donini CF; Nguyen NT; Lincet H; Vendrell JA
Oncotarget; 2015 Dec; 6(39):41566-81. PubMed ID: 26431164
[TBL] [Abstract][Full Text] [Related]
3. ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells.
Thollet A; Vendrell JA; Payen L; Ghayad SE; Ben Larbi S; Grisard E; Collins C; Villedieu M; Cohen PA
Mol Cancer; 2010 Nov; 9():291. PubMed ID: 21059223
[TBL] [Abstract][Full Text] [Related]
4. Implication of
Smeester BA; Draper GM; Slipek NJ; Larsson AT; Stratton N; Pomeroy EJ; Becklin KL; Yamamoto K; Williams KB; Laoharawee K; Peterson JJ; Abrahante JE; Rathe SK; Mills LJ; Crosby MR; Hudson WA; Rahrmann EP; Largaespada DA; Moriarity BS
Mol Cancer Ther; 2020 Dec; 19(12):2528-2541. PubMed ID: 32999043
[TBL] [Abstract][Full Text] [Related]
5. ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells.
Krig SR; Miller JK; Frietze S; Beckett LA; Neve RM; Farnham PJ; Yaswen PI; Sweeney CA
Oncogene; 2010 Oct; 29(40):5500-10. PubMed ID: 20661224
[TBL] [Abstract][Full Text] [Related]
6. Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad.
Quinlan KG; Verger A; Yaswen P; Crossley M
Biochim Biophys Acta; 2007 Jun; 1775(2):333-40. PubMed ID: 17572303
[TBL] [Abstract][Full Text] [Related]
7. SAP domain-dependent Mkl1 signaling stimulates proliferation and cell migration by induction of a distinct gene set indicative of poor prognosis in breast cancer patients.
Gurbuz I; Ferralli J; Roloff T; Chiquet-Ehrismann R; Asparuhova MB
Mol Cancer; 2014 Feb; 13():22. PubMed ID: 24495796
[TBL] [Abstract][Full Text] [Related]
8. ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion.
Vendrell JA; Thollet A; Nguyen NT; Ghayad SE; Vinot S; Bièche I; Grisard E; Josserand V; Coll JL; Roux P; Corbo L; Treilleux I; Rimokh R; Cohen PA
Cancer Res; 2012 Jul; 72(14):3593-606. PubMed ID: 22593193
[TBL] [Abstract][Full Text] [Related]
9. ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction.
Huang G; Krig S; Kowbel D; Xu H; Hyun B; Volik S; Feuerstein B; Mills GB; Stokoe D; Yaswen P; Collins C
Hum Mol Genet; 2005 Nov; 14(21):3219-25. PubMed ID: 16203743
[TBL] [Abstract][Full Text] [Related]
10. MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer.
Bai WD; Ye XM; Zhang MY; Zhu HY; Xi WJ; Huang X; Zhao J; Gu B; Zheng GX; Yang AG; Jia LT
Int J Cancer; 2014 Sep; 135(6):1356-68. PubMed ID: 24615544
[TBL] [Abstract][Full Text] [Related]
11. Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha.
Frietze S; O'Geen H; Littlepage LE; Simion C; Sweeney CA; Farnham PJ; Krig SR
BMC Genomics; 2014 Jun; 15(1):520. PubMed ID: 24962896
[TBL] [Abstract][Full Text] [Related]
12. High levels of Hsp90 cochaperone p23 promote tumor progression and poor prognosis in breast cancer by increasing lymph node metastases and drug resistance.
Simpson NE; Lambert WM; Watkins R; Giashuddin S; Huang SJ; Oxelmark E; Arju R; Hochman T; Goldberg JD; Schneider RJ; Reiz LF; Soares FA; Logan SK; Garabedian MJ
Cancer Res; 2010 Nov; 70(21):8446-56. PubMed ID: 20847343
[TBL] [Abstract][Full Text] [Related]
13. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
[TBL] [Abstract][Full Text] [Related]
14. Learning the local Bayesian network structure around the ZNF217 oncogene in breast tumours.
Prestat E; de Morais SR; Vendrell JA; Thollet A; Gautier C; Cohen PA; Aussem A
Comput Biol Med; 2013 May; 43(4):334-41. PubMed ID: 23375235
[TBL] [Abstract][Full Text] [Related]
15. A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers.
Nguyen NT; Vendrell JA; Poulard C; Győrffy B; Goddard-Léon S; Bièche I; Corbo L; Le Romancer M; Bachelot T; Treilleux I; Cohen PA
Mol Oncol; 2014 Dec; 8(8):1441-57. PubMed ID: 24973012
[TBL] [Abstract][Full Text] [Related]
16. Dimethyl fumarate inhibits ZNF217 and can be beneficial in a subset of estrogen receptor positive breast cancers.
Sharma T; Zhang Y; Zigrossi A; Cravatt BF; Kastrati I
Breast Cancer Res Treat; 2023 Oct; 201(3):561-570. PubMed ID: 37477798
[TBL] [Abstract][Full Text] [Related]
17. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
[TBL] [Abstract][Full Text] [Related]
18. Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.
Rojo F; González-Navarrete I; Bragado R; Dalmases A; Menéndez S; Cortes-Sempere M; Suárez C; Oliva C; Servitja S; Rodriguez-Fanjul V; Sánchez-Pérez I; Campas C; Corominas JM; Tusquets I; Bellosillo B; Serrano S; Perona R; Rovira A; Albanell J
Clin Cancer Res; 2009 May; 15(10):3530-9. PubMed ID: 19417026
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors.
Mao XG; Yan M; Xue XY; Zhang X; Ren HG; Guo G; Wang P; Zhang W; Huo JL
Lab Invest; 2011 Jul; 91(7):1068-78. PubMed ID: 21483406
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11.
Bockhorn J; Dalton R; Nwachukwu C; Huang S; Prat A; Yee K; Chang YF; Huo D; Wen Y; Swanson KE; Qiu T; Lu J; Park SY; Dolan ME; Perou CM; Olopade OI; Clarke MF; Greene GL; Liu H
Nat Commun; 2013; 4():1393. PubMed ID: 23340433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
